logo-loader
viewAchieve Life Sciences Inc

Achieve Life Sciences shares rocket after a promising smoking-cessation drug trial

The trial evaluated the effectiveness of the drug cytisinicline on smoking cessation

cigarettes
Achieve Life Sciences is a pharmaceutical group specializing in smoking-cessation techniques

Achieve Life Sciences Inc (NASDAQ:ACHV) shares soared triple digits on Friday on the back of upbeat news from the company's trial of its smoking-cessation drug, cytisinicline.

According to the company, the trial evaluated the effectiveness of the drug cytisinicline on smoking cessation. The plant-based compound, also known as cytisine, interacts with the brain’s nicotine receptors to reduce nicotine withdrawal symptoms.

Shares of the Washington State-based biotech more than doubled to US$3.90.

READ: ImmunoPrecise Antibodies clinches contract from Leidos Biomedical Research

"Given the short 25-day treatment period, the abstinence rates observed are impressive, particularly since subjects were not required to commit to quitting and received minimal behavioral support during the study. These results continue to support our belief that cytisinicline could be a well-tolerated and effective potential treatment option for the millions of people who are battling nicotine addiction," said chief medical officer Dr. Cindy Jacobs.

A total of 26 smokers participated in the study, who smoked an average of 17.2 cigarettes a day. 

The randomized study used 1.5mg and 3mg  doses of cytisinicline over 25 days. 

"All subjects had a significant and immediate reduction in cigarettes smoked within two days of initiating cytisinicline treatment," said the company in a release, adding that by day 26, study participants had an average reduction of 80% in the number of cigarettes smoked during treatment.

Additionally, there was an 82% reduction in expired carbon monoxide and 46% of participants stopped smoking.

According to the company, cytisinicline was well tolerated, with only "transient, mild-to-moderate headache" as the most common side-effect. 

Contact Katie Lewis at [email protected]

 

Quick facts: Achieve Life Sciences Inc

Price: 0.316 USD

NASDAQ:ACHV
Market: NASDAQ
Market Cap: $9.91 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Helix Technologies following up strong 2019 with success in 2020

Helix Technologies (OTCQB: HLIX) President of Data Services Garvis Toler joined Steve Darling from Proactive Vancouver to discuss the company releasing their 2019 financial numbers which were very strong and also what milestones they hit to close the year.  Toler also told Proactive...

2 days, 16 hours ago

2 min read